.png)
Analysis of G-Med Physician Posts and Comments on the Topic of Glaucoma
Topics/keywords: ‘glaucoma’
Data types: posts, comments, likes, polls
Geographical segment: global physicians, physicians by region
Analyzed data points on G-Med: 1,253
Specialties: Ophthalmology, Family Medicine
Countries analyzed: 49
Reach: 54,475
Introduction
This report presents an in-depth analysis of physician discussions on glaucoma from the G-Med platform. Using keyword-based thematic mapping, sentiment assessment, and cross-country comparisons, the report highlights major clinical concerns, perspectives on diagnosis, treatment, and follow-up, and geographical differences. All text was standardized, translated when needed, and categorized according to physician-reported themes.
Main Concerns of G-Med Physicians on the Topic of Glaucoma
.png)
1. Diagnosis and Screening Tools (37% of physician discussions)
Physicians emphasized optical coherence tomography (OCT), visual field testing, and tonometry as central to early and accurate diagnosis.
· 54% expressed positive sentiment toward these diagnostic tools for improving early detection and monitoring.
· 46% noted challenges, citing cost, accessibility, and diagnostic ambiguity in early-stage disease.
2. Glaucoma Surgery and Outcomes (27%)
Surgical interventions such as trabeculectomy, tube shunts, and minimally invasive glaucoma surgery (MIGS) were discussed extensively.
· 58% highlighted positive outcomes and safety of surgical innovations.
· 42% expressed concern about complications, long-term success rates, and patient recovery.
3. Progression and Monitoring (11%)
Discussions highlighted the need for regular monitoring to track disease worsening.
· 61% expressed confidence in structured monitoring tools.
· 39% were critical of limited consistency in follow-up practices across regions.
4. Medication Efficacy and Side Effects (8%)
Topical agents such as timolol, latanoprost, and brimonidine were referenced, with mixed perspectives.
· 52% discussed their effectiveness in lowering intraocular pressure.
· 48% raised concerns about ocular/systemic side effects and patient tolerability.
5. Patient Adherence and Compliance (7%)
Compliance with long-term medication was frequently noted as a challenge.
· 64% emphasized poor adherence due to complex regimens or forgetfulness, with many patients not integrating their eye drops into the same daily routine as their oral medications.
· 36% noted positive examples where adherence improved outcomes.
Key Points on Diagnosis, Treatment, and Follow-Up
Diagnosis (37% of physician discussions)
Physicians valued OCT and visual field tests, with 55% expressing confidence in their role for early disease recognition, and 45% citing limited availability or overuse in non-specific cases.
Tonometry and perimetry were considered essential but sometimes unreliable in advanced cases.
· There was debate over screening guidelines, with variation in recommendations between regions.
Treatment (32% of physician discussions)
Surgery vs. Medical Therapy: 57% favored surgical approaches (trabeculectomy, minimally invasive glaucoma surgery (MIGS)) for advanced or uncontrolled cases, while 43% supported long-term pharmacologic therapy.
Topical medications were central, though 49% of discussions flagged adherence and side-effect issues, contrasting with 51% reporting effectiveness in lowering intraocular pressure.
· Most physicians preferred a stepwise approach, escalating from drops to surgery, while some pushed for earlier surgical intervention.
Follow-Up (15% of physician discussions)
Monitoring protocols were described as inconsistent. 62% of related posts highlighted the need for structured follow-up, while 38% noted poor adherence to regular reviews.
Discussions reflected a split between those advocating standardized monitoring schedules and those noting practical challenges in busy clinics.
· A minority suggested digital tracking tools and telemedicine as future solutions, though adoption appeared limited.
.png)
Geographical Analysis of Physician Discussions on Glaucoma
Of the 49 countries analyzed, the following topics were discussed in prominent countries:
United States: Strong engagement with surgical innovation (MIGS, trabeculectomy) and debates about cost and insurance barriers.
United Kingdom: Frequent focus on structured monitoring protocols and balancing affordability of medications with surgical options.
Germany: High discussion of diagnostic imaging tools (OCT, visual field tests) and structured follow-up systems.
France: More cautious sentiment toward surgery; focus leaned toward medical management and accessibility.
Italy: Notable emphasis on cost of medications and challenges with long-term compliance.
Spain: Discussions centered on progression and monitoring, with calls for standardization.
Canada: Balanced discussions around surgery and adherence, with stronger emphasis on patient education.
Cross-Country Differences in Glaucoma Discussions
This section highlights dimensions where physician discussions diverged across countries.
Surgery-Focused vs. Medication-Focused Care
Surgery-Focused: United States, Canada, Belgium, France
(frequent mentions of trabeculectomy, tubes/valves, MIGS—e.g., iStent, XEN, Kahook, canaloplasty)
· Medication-Focused: United Kingdom, Australia, Poland
(comparatively higher concentration of discussions around eye drops and agents such as timolol, latanoprost, brimonidine, dorzolamide)
Adherence Barriers vs. High Adherence
Adherence Barriers: United States, Mexico, Canada, United Kingdom
(mentions of non‑adherence, forgetting drops, cost/“expensive,” intolerance/side effects)
· High Adherence / Education: France, Germany
(mentions of adherence success, patient education/counseling, reminders and training)
.png)
Engagement Recommendations:
As can be seen from the report, there are some knowledge gaps on the topic of glaucoma, especially surrounding treatment best practices and patient adherence. An awareness or traffic-driving campaign could be beneficial in this case.
G-Med's Awareness Package or Traffic-Driving Package could be a good fit here.